(653) Tixagevimab and Cilgavimab Reduced the Likelihood of Covid after Heart Transplant in the Age of Omicron

PURPOSE: SARS-CoV-2 infection (COVID) is associated with high morbidity and mortality in solid organ transplants and vaccine efficacy is suboptimal. Tixagevimab and cilgavimab (T/C) are neutralizing antibodies used in the U.S. under emergency use authorization for COVID pre-exposure prophylaxis. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, R., Henricksen, E.J., Kim, D.T., Luikart, H., Moayedi, Y., Wayda, B., Guenthart, B., Teuteberg, J., Khush, K., Subramanian, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068099/
http://dx.doi.org/10.1016/j.healun.2023.02.667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068099/
http://dx.doi.org/10.1016/j.healun.2023.02.667

Ejemplares similares